In vivo validation of a novel class of pain medication

SUMMARY

Although pain research has identified a plethora of targets, no truly innovative analgesics have reached the market in the past years, mostly due to low efficacy or severe side effects. This leaves a significant unmet medical need for novel, safe and effective compounds with reduced side effect burden and abuse liability.

The project seeks to complete external validation of in vivo data on NFEPP, a novel compound that has demonstrated potent pain relief without addiction potential in initial experiments. A patent has been filed and results were published in Science in 2017.

PROJECT GOALS

• External validation of preclinical in vivo studies
• Secure follow-on applied research funding

LONG-TERM GOALS

• Further develop under CMC and GMP conditions
• Test safety & toxicity of NFEPP
• Perform phase I/IIa clinical trials
• License to Pharma

PRINCIPAL INVESTIGATORS:
Dr. Viola Seitz
Prof. Dr. Christoph Stein
Charité